Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 30, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not contain financial performance data.
Material Changes
The filing details two specific transactions involving the SmithKline Beecham Employee Benefit Trust ("the Trust") on August 29, 2006:
- Sale of Shares: 260 Ordinary shares were sold on behalf of participants in the GlaxoSmithKline Annual Investment Plan at a price of GBP 14.50 per share.
- Transfer of Shares: 857 Ordinary shares were transferred from the Trust to a participant in the GlaxoSmithKline Annual Investment Plan.
Director Mr. J S Heslop is noted as having an interest in the shares held in the fund, consistent with other non-US employees or former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total volume of shares traded by the Trust during the reporting period to assess the scale of employee plan activity.
- Confirm the current share price relative to the GBP 14.50 transaction price mentioned in the filing.
- Review the full composition of the SmithKline Beecham Employee Benefit Trust to understand the scope of Director J S Heslop's indirect interest.